Viatris Inc
NASDAQ:VTRS
Viatris Inc
Operating Income
Viatris Inc
Operating Income Peer Comparison
Competitive Operating Income Analysis
Latest Figures & CAGR of Competitors
Company | Operating Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Viatris Inc
NASDAQ:VTRS
|
Operating Income
$1.6B
|
CAGR 3-Years
3%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
2%
|
|
Johnson & Johnson
NYSE:JNJ
|
Operating Income
$23.4B
|
CAGR 3-Years
3%
|
CAGR 5-Years
3%
|
CAGR 10-Years
3%
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Operating Income
$10.8B
|
CAGR 3-Years
22%
|
CAGR 5-Years
7%
|
CAGR 10-Years
13%
|
|
Pfizer Inc
NYSE:PFE
|
Operating Income
$13.1B
|
CAGR 3-Years
4%
|
CAGR 5-Years
8%
|
CAGR 10-Years
-3%
|
|
Merck & Co Inc
NYSE:MRK
|
Operating Income
$4.1B
|
CAGR 3-Years
-28%
|
CAGR 5-Years
-19%
|
CAGR 10-Years
-7%
|
|
Eli Lilly and Co
NYSE:LLY
|
Operating Income
$10.3B
|
CAGR 3-Years
15%
|
CAGR 5-Years
12%
|
CAGR 10-Years
6%
|
See Also
What is Viatris Inc's Operating Income?
Operating Income
1.6B
USD
Based on the financial report for Dec 31, 2023, Viatris Inc's Operating Income amounts to 1.6B USD.
What is Viatris Inc's Operating Income growth rate?
Operating Income CAGR 10Y
2%
Over the last year, the Operating Income growth was -42%. The average annual Operating Income growth rates for Viatris Inc have been 3% over the past three years , -2% over the past five years , and 2% over the past ten years .